Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Swaminathan P. Iyer, Shaker Dakhil, Michi M. Shinohara, Jasmine Zain, Mark Acosta, Francine Foss

Blood Neoplasia (2025) 2 (1): 100055.

https://doi.org/10.1016/j.bneo.2024.100055

Published: 2025

Journal Articles

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Jongseok Kang, Jason Ostergaard, Xiaohong Wang, Peter M. Gordon

Blood Neoplasia (2025) 2 (1): 100057.

https://doi.org/10.1016/j.bneo.2024.100057

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Matthew S. Davids, Jacob Ambrose, Enrico de Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z. H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching Kun Wang, Mazyar Shadman

Blood Neoplasia (2025) 2 (1): 100047.

https://doi.org/10.1016/j.bneo.2024.100047

Published: 2025

Includes: Supplemental data

Journal Articles

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Hiroki Kobayashi, Ryota Chijimatsu, Yusuke Naoi, Yoshihiro Otani, Ryo Mizuta, Kentaro Fujii, Joji Ishida, Hiroyuki Murakami, Hideki Ujiie, Kazuhiro Ikeuchi, Tomohiro Urata, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Nobuharu Fujii, Ken-ichi Matsuoka, Yasuharu Sato, Yoshinobu Maeda, Daisuke Ennishi

Blood Neoplasia (2025) 2 (1): 100058.

https://doi.org/10.1016/j.bneo.2024.100058

Published: 2025

Includes: Supplemental data

Journal Articles

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Julia Erin Wiedmeier-Nutor, Michael A. Golafshar, Katie L. Kunze, Edward D. Esplin, Robert L. Nussbaum, Erik Jessen, Brandie Heald, A. Keith Stewart, N. Jewel Samadder, P. Leif Bergsagel, Rafael Fonseca

Blood Neoplasia (2025) 2 (1): 100045.

https://doi.org/10.1016/j.bneo.2024.100045

Published: 2025

Includes: Supplemental data

Journal Articles

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

David T. Yeung, Laura N. Eadie, Jacqueline Rehn, Susan L. Heatley, Barbara J. McClure, Elyse C. Page, Caitlin E. Schutz, Michael P. Osborn, Toby Trahair, Rosemary Sutton, Michelle J. Henderson, John Kwan, Sally Mapp, Luciano Dalla-Pozza, Kenneth Bradstock, Matthew Greenwood, Deborah L. White

Blood Neoplasia (2025) 2 (1): 100041.

https://doi.org/10.1016/j.bneo.2024.100041

Published: 2025

Includes: Supplemental data

Journal Articles

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL

Willem P. J. Cox, Noël M. M. Dautzenberg, Linde Dekker, Tesa Klenovsek, Annelisa M. Cornel, Marliek van Hoesel, Dorette S. van Ingen Schenau, Reno S. Bladergroen, Roland P. Kuiper, Laurens T. van der Meer, Friso G. Calkoen, Stefan Nierkens, Frank N. van Leeuwen

Blood Neoplasia (2025) 2 (1): 100060.

https://doi.org/10.1016/j.bneo.2024.100060

Published: 2025

Includes: Supplemental data

Journal Articles

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Lawrence A. Stern, Vibhuti Vyas, Laura Lim, Christian Huynh, Ryan Urak, Ruby Espinosa, Zhiqiang Wang, Michalina Silva Thiel, John C. Williams, Stephen J. Forman, Christine E. Brown, Xiuli Wang

Blood Neoplasia (2024) 1 (4): 100048.

https://doi.org/10.1016/j.bneo.2024.100048

Published: 2024

Includes: Supplemental data

Journal Articles

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

Blood Neoplasia (2024) 1 (4): 100049.

https://doi.org/10.1016/j.bneo.2024.100049

Published: 2024

Includes: Supplemental data

Journal Articles

Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling

Hamed Bashiri, Ahad Khalilnezhad, Haruhito Totani, Joe Yeong, Tae-Hoon Chung, Felicia Wee, Yuezhen Xue, Zhen Wei Neo, Li Yen Chong, Wee Joo Chng, Atsushi Watanabe, Siok-Bian Ng, The Phyu, Toshio Suda

Blood Neoplasia (2024) 1 (4): 100046.

https://doi.org/10.1016/j.bneo.2024.100046

Published: 2024

Includes: Supplemental data

Journal Articles

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy

Blood Neoplasia (2024) 1 (4): 100044.

https://doi.org/10.1016/j.bneo.2024.100044

Published: 2024

Includes: Supplemental data

Journal Articles

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

Eunice Lai, Yu Yang Soon, Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Cinnie Yentia Soekojo, Melissa Ooi, Wee Joo Chng, Sanjay de Mel

Blood Neoplasia (2024) 1 (4): 100042.

https://doi.org/10.1016/j.bneo.2024.100042

Published: 2024

Includes: Supplemental data

Journal Articles

BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis

Wangisa Dunuwille, William C. Wilson, Hassan Bjeije, Nancy Issa, Wentao Han, Tyler M. Parsons, Andrew L. Young, Infencia Xavier Raj, Aishwarya Krishnan, Tarang Gaur, Eunice S. Wang, Andrew P. Weng, Matthew C. Stubbs, Hamza Celik, Amanda F. Cashen, John R. Edwards, Grant A. Challen

Blood Neoplasia (2024) 1 (4): 100040.

https://doi.org/10.1016/j.bneo.2024.100040

Published: 2024

Includes: Supplemental data

Journal Articles

COVID-19 vaccination in patients with classic and variant hairy cell leukemia

Robert J. Kreitman, Lacey James, Julie Feurtado, Holly Eager, Olena Sierra Ortiz, Mory Gould, Isaac Shpilman, Hong Zhou, Peter D. Burbelo, Jeffrey I. Cohen, Hao-Wei Wang, Constance M. Yuan, Evgeny Arons

Blood Neoplasia (2024) 1 (4): 100035.

https://doi.org/10.1016/j.bneo.2024.100035

Published: 2024

Journal Articles

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

Paola Ghione, Kurt S. Bantilan, Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron, Paul Hamlin, Anita Kumar, Matthew Matasar, Colette Owens, Alison Moskowitz, Lorenzo Falchi, David Straus, Steven Horwitz, Gilles Salles, Ahmet Dogan, Andrew D. Zelenetz

Blood Neoplasia (2024) 1 (4): 100031.

https://doi.org/10.1016/j.bneo.2024.100031

Published: 2024

Journal Articles

Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation

Jinjun Cheng, Rachel Mariani, Jyotinder Nain Punia, Marimar de la Cruz Bonilla, Pichayut Nithagon, Metin Ozdemirli, Wen Shuai, Larry Wang, Oussama Abla, Shunyou Gong

Blood Neoplasia (2024) 1 (4): 100039.

https://doi.org/10.1016/j.bneo.2024.100039

Published: 2024

Includes: Supplemental data

Journal Articles

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

Ella Troy, Joseph Caporale, Yasemin Sezgin, Marcelo S. F. Pereira, Gregory Behbehani, Justin Lyberger, Dean A. Lee, Meisam Naeimi Kararoudi

Blood Neoplasia (2024) 1 (4): 100032.

https://doi.org/10.1016/j.bneo.2024.100032

Published: 2024

Includes: Supplemental data

Journal Articles

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions

Emma Kroeze, Michelle M. Kleisman, Rico Hagelaar, Reno S. Bladergroen, Lennart A. Kester, Marijn A. Scheijde-Vermeulen, Freerk van Dijk, Jules P. P. Meijerink, Roland P. Kuiper, Jan L. C. Loeffen

Blood Neoplasia (2024) 1 (3): 100029.

https://doi.org/10.1016/j.bneo.2024.100029

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

Natalia Timofeeva, Nitin Jain, Varsha Gandhi

Blood Neoplasia (2024) 1 (3): 100034.

https://doi.org/10.1016/j.bneo.2024.100034

Published: 2024

Journal Articles

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study

Blood Neoplasia (2024) 1 (3): 100033.

https://doi.org/10.1016/j.bneo.2024.100033

Published: 2024

Includes: Supplemental data

NARROW

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

Cerebrospinal fluid attenuates the efficacy of methotrexate against acute lymphoblastic leukemia cells

Real-world characteristics, treatment patterns, and outcomes of patients with 2 or more LOTs for CLL/SLL in the United States

Single-cell and spatial characterization of plasmablast-like lymphoma cells in primary central nervous system lymphoma

Pathogenic germ line variants in a prospective multicenter cohort of patients with multiple myeloma

Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol

Loss of p53 impairs death receptor expression and confers resistance to CD19 CAR T-cell therapy in BCP-ALL

Development and characterization of a low-affinity humanized CD19 chimeric antigen receptor for B-cell malignancies

Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

Deciphering MARCH5’s impact on multiple myeloma: insights into autophagy regulation and AKT-FOXO3 signaling

Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy

Lenalidomide, ixazomib, or daratumumab maintenance therapy in multiple myeloma

BIRC5 upregulation enhances DNMT3A-mutant T-ALL cell survival and pathogenesis

COVID-19 vaccination in patients with classic and variant hairy cell leukemia

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

Clinical and pathological features of pediatric peripheral T-cell lymphoma after solid organ transplantation

CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies

T-cell lymphoblastic lymphoma compared with T-cell acute lymphoblastic leukemia: similar subtypes and different fusions

Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice

Augmented use of L-asparaginase markedly improves AYA ALL outcomes: FBMTG prospective MRD2014 study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only